|Bid||7.28 x 800|
|Ask||7.50 x 800|
|Day's Range||7.20 - 7.58|
|52 Week Range||7.20 - 52.72|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.40|
AUBURN, Ala., May 17, 2019 /PRNewswire/ -- The first clinical trial of a gene therapy treatment created through a research alliance between Auburn University and the University of Massachusetts has been administered in a child at the National Institutes of Health, or NIH, in Bethesda, Maryland. The NIH clinical trial is a significant milestone for GM1 gangliosidosis, a deadly disease with no approved treatment.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced dosing of the first patient in a clinical study of AXO-AAV-GM1 (also known as AAV9-GLB1), an investigational gene therapy for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a 1-for-8 basis will become effective on May 7, 2019. The shares will begin trading on the split-adjusted basis on the Nasdaq Global Select Market under the Company's existing trading symbol "AXGT" on May 8, 2019. The new CUSIP number following the reverse share split will be G0750W203. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019.
Axovant Sciences Ltd NASDAQ/NGS:AXGTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for AXGT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AXGT are favorable, with net inflows of $687 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients. “We are pleased to begin enrolling additional patients in the SUNRISE-PD study at a higher dose level, following encouraging 3-month data from the first cohort,” said Dr. Gavin Corcoran, Axovant’s Chief Research and Development Officer. “We look forward to exploring the full clinical potential of AXO-Lenti-PD in patients with Parkinson’s disease, building upon the safety profile and improvements in motor symptoms that have been observed in 17 patients evaluated across the ProSavin and AXO-Lenti-PD programs.
Axovant Gene Therapies Ltd. (NASDAQ:AXGT) shareholders should be happy to see the share price up 19% in the last quarter. But only the myopic could ignore the astounding decline over three years. The share price has sunk l...
-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to.
Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that its Board of Directors and a majority of its shareholders have approved a reduction of issued and outstanding common shares on a 1-for-8 basis that is expected to become effective in May 2019. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019. The Company also noted the closing of the public offering of common shares in March 2019 for gross proceeds of $40 million with participation from leading institutional shareholders.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced additional data and plans for the AXO-AAV-GM2 and AXO-Lenti-PD programs, which will be highlighted at the Company’s R&D day for investors and analysts.
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Axovant Sciences (AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share. Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,000,000 of its common shares on the same terms and conditions. The offering is expected to close on March 18, 2019, subject to customary closing conditions.
Axovant Sciences (AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase additional common shares in the offering on the same terms and conditions.
Smaller gene therapy biotechs are taking the spotlight given the M&A interest surrounding them. One such gene therapy company saw its shares rallying by more than 30 percent Monday following the release ...
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.
Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported three-month data from an investigator-initiated study administering investigational AXO-AAV-GM2 gene therapy in a patient with advanced infantile Tay-Sachs disease, a rare and fatal pediatric neurodegenerative genetic disorder characterized by impaired β-Hexosaminidase A enzyme production. AXO-AAV-GM2 is an investigational gene therapy designed to restore β-Hexosaminidase A enzyme activity in the central nervous system.
Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. The cohort consisted of two patients with advanced Parkinson’s disease who received a one-time administration of the lowest dose of AXO-Lenti-PD (4.2x106 TU). “Our focus in this first cohort of the SUNRISE-PD study was on the safety and tolerability of AXO-Lenti-PD, as well as the evaluation of efficacy using well-validated, objective measures.